Market Research Logo

Global HER2-Negative Breast Cancer Market 2015-2019

About HER2-negative breast cancer

HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.

Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. Based on type of drug molecule, the market is segmented as follows:

  • Biologics
  • Small molecules
Based on route of administration, the market is segmented as follows:
  • Oral
  • Parenteral
This report includes a discussion of the market in the following three regions:
  • Americas (the US, Canada, Mexico, and Brazil)
  • EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
  • APAC (Japan, China, Australia, Singapore, South Korea, and India)
Technavio's report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
  • Americas
  • APAC
  • EMEA
Key vendors
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
Other prominent vendors
  • AbbVie
  • AstraZeneca
  • BioMarin
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly
  • Galena Biopharma
  • Incyte
  • Merck
  • Merck Serono
  • Merrimack
  • Nektar
  • Tesaro
Key market driver
  • Significant unmet needs
  • For a full, detailed list, view our report
Key market challenge
  • Premium-priced therapies
  • For a full, detailed list, view our report
Key market trend
  • Emerging therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global HER2-Negative Breast Cancer Market 2015-2019

Technavio recognizes the following companies as the key players in the Global HER2-Negative Breast Cancer Market: F. Hoffmann-La Roche, Novartis and Pfizer

Other Prominent Vendors in the market are: AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai, Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, and Tesaro.

Commenting on the report, an analyst from Technavio’s team said: “An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies.

According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters.

Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients.

Companies Mentioned

F. Hoffmann-La Roche, Novartis, Pfizer, AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai, Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, Tesaro.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global HER2-negative breast cancer market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of drug molecule
    • Biologics
    • Small molecules
  • Market segmentation by route of administration
    • Oral
    • Parenteral
  • Geographical segmentation
    • Market segmentation by geography 2014-2019
      • Table Segmentation of global HER2-negative breast cancer market by geography 2014
    • HER2-negative breast cancer market in Americas 2014-2019
      • Table HER2-negative breast cancer market in Americas 2014-2019 ($ millions)
    • HER2-negative breast cancer market in EMEA 2014-2019
      • Table HER2-negative breast cancer market in EMEA 2014-2019 ($ millions)
    • HER2-negative breast cancer market in APAC 2014-2019
      • Table HER2-negative breast cancer market in APAC 2014-2019 ($ millions)
      • Table Region-wise comparison of market size 2014-2019 ($ millions)
  • Pipeline portfolio
    • Table Major pipeline drug candidates in phase III stage of development
    • Key information about late-stage pipeline candidates
  • Market drivers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
    • Key news
    • Mergers and acquisitions
    • Market share analysis
      • Table Vendor ranking 2014
      • Table Key takeaways: F. Hoffmann-La Roche
      • Table Novartis: Sales and YoY growth of Afinitor 2012-2014 ($ millions)
      • Table Key takeaways: Novartis
      • Table Key takeaways: Pfizer
    • Other and future prominent vendors
  • Key vendor analysis
    • F. Hoffmann-La Roche
    • Novartis
      • Table Business segmentation 2013 and 2014 by revenue ($ billions)
    • Pfizer
      • Table Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report